Multinational Biopharmaceutical Company
Active 2007–2026. The register lists this client once for every firm that files on its behalf; all 34 of its records are shown together here.
These two figures are not added together. A client that lobbies for itself reports its own spending, while firms it retains report what they were paid. Disclosure rules ask the in-house figure to include those payments, but filings do not always do so, and a filing gives no way to tell. Each is shown as reported.
| Year | Firm | Period | Amount | Doc |
|---|---|---|---|---|
| 2026 | TARPLIN, DOWNS & YOUNG, LLC |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$60,000 | |
| 2026 | NOVARTIS |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$840,000 | |
| 2026 | BGR GOVERNMENT AFFAIRS |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$60,000 | |
| 2026 | MONUMENT ADVOCACY |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$60,000 | |
| 2026 | TIBER CREEK HEALTH STRATEGIES, INC. |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report (No Activity) |
$60,000 | |
| 2026 | BROWNSTEIN HYATT FARBER SCHRECK, LLP |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$90,000 | |
| 2026 | DLA PIPER LLP (US) |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$60,000 | |
| 2026 | CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$50,000 | |
| 2026 | TARPLIN, DOWNS & YOUNG, LLC |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
$60,000 | |
| 2026 | DLA PIPER LLP (US) |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
$60,000 |
| Issue | Activities |
|---|---|
| Health Issues | 657 |
| Medicare/Medicaid | 408 |
| Budget/Appropriations | 259 |
| Taxation/Internal Revenue Code | 248 |
| Trade (domestic/foreign) | 160 |
| Copyright/Patent/Trademark | 120 |
| Medical/Disease Research/Clinical Labs | 81 |
| Labor Issues/Antitrust/Workplace | 35 |
| Government Issues | 24 |
| Veterans | 22 |
| Pharmacy | 22 |
| Foreign Relations | 20 |
| Science/Technology | 13 |
| Animals | 6 |
| Energy/Nuclear | 5 |